Metastases to the breast are well documented with cutaneous melanoma, pulmonary and gynaecological tumours accounting for the majority. It is important to consider metastatic tumour in the differential diagnosis when presented with unusual clinical or radiological findings. This study illustrates multi-system clinical findings and highlights the diversity of imaging findings in metastases to the breast. It demonstrates how metastatic melanoma treatment has been revolutionised by the introduction of targeted therapies and immunotherapy with a dramatic response to treatment with a B-raf proto-oncogene (BRAF) and Mitogen-activated protein kinase (MEK) inhibitors combination.